• View the Talks
• 64 min
  1. Current trends in antiviral drug development

  • Prof. Dr. Erik De Clercq
• 76 min
  2. Antivirals versus vaccines

  • Prof. Albert D.M.E. Osterhaus
• 58 min
  3. Prospects of anti-HIV therapy and prophylaxis

  • Prof. Dr. Erik De Clercq
• 38 min
  4. Systemic RNA interference (RNAi) therapeutics for the treatment of HIV-1

  • Prof. John Rossi
• 9 min
  5. The path towards a cure for chronic hepatitis B

  • Prof. Fabien Zoulim
• 70 min
  6. Influenza antivirals: update

  • Prof. Frederick G. Hayden
• 35 min
  7. Herpes simplex virus and varicella-zoster virus helicase-primase inhibitors

  • Dr. Hugh J. Field
• 45 min
  8. Nucleoside phosphonates as inhibitors of HIV

  • Dr. Tomas Cihlar
• 59 min
  9. HIV-1 integrase inhibitors

  • Prof. Martin Markowitz
• 52 min
  10. Cellular cofactors of HIV integrase: from target identification to discovery of ledgins

  • Prof. Zeger Debyser
• 32 min
  11. HIV entry inhibitors

  • Prof. José Esté
• 39 min
  12. Antiviral therapy of orthopoxvirus infection

  • Prof. Earl R. Kern
  • Prof. Mark N. Prichard
• 25 min
  13. Herpes simplex virus antiviral chemotherapy

  • Dr. Hugh J. Field
• 30 min
  14. Cyclophilin inhibitors for HCV

  • Prof. Robert Flisiak
• Archived Lectures *These may not cover the latest advances in the field
• 50 min
  15. Towards the development of potent therapy against the hepatitis C virus

  • Prof. Johan Neyts
• 62 min
  16. Antiviral therapy of chronic hepatitis B virus infections: is resistance still a challenge?

  • Prof. Fabien Zoulim

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. HIV life cycle
3. The HIV-1 genome
4. Synthesis of HIV-1 envelope glycoproteins
5. HIV life cycle: targets for antiretroviral therapy
6. Mechanism of HIV-1 entry
7. HIV-1 binding inhibitors
8. Polyanions as inhibitors of HIV attachment
9. Small-molecule inhibitors of CD4-gp120 interaction
10. HIV-1 coreceptor inhibitors
11. Coreceptor usage of HIV-1 variants
12. Viral composition of pure/mixed populations
13. CXCR4 antagonists with potent anti-HIV activity
14. Drugs blocking gp120 - CCR5 interaction
15. Maraviroc
16. Activity of maraviroc
17. MOTIVATE 1 and 2 clinical trials
18. Coreceptor tropism by treatment status
19. Resistance in the absence of coreceptors
20. Second generation HIV entry inhibitors
21. HIV-1 fusion inhibitors
22. Mechanism of gp41 dependant fusion
23. Fusion inhibitors: enfuvirtide (T20)
24. TORO trials
25. Predictors of virological response
26. Limitations for the use of enfuvirtide
27. Resistance to enfuvirtide
28. Second generation fusion inhibitors
29. The discovery of virus-inhibitory peptide (virip)
30. Pilot phase I/II clinical trial of vir576
31. Future perspectives for HIV entry
32. Future perspectives for HIV entry: gene therapy
33. New strategies to prevent HIV infection
34. Hematopoietic cells targeted to CCR5
35. Conclusions

Topics Covered

• HIV life cycle
• The HIV-1 genome
• Synthesis of HIV-1 envelope glycoproteins
• Targets for antiretroviral therapy
• Mechanism of HIV-1 entry
• HIV entry inhibition
• HIV-1 binding inhibitors
• HIV-1 coreceptor inhibitors
• Viral composition of pure/mixed populations
• CXCR4 antagonists
• Drugs blocking gp120-CCR5 interaction
• Maraviroc
• MOTIVATE 1 and 2 clinical trials
• Coreceptor tropism by treatment status
• Resistance in the absence of coreceptors
• HIV-1 fusion inhibitors
• TORO trials
• Predictors of virological response
• The virus-inhibitory peptide (virip)
• New strategies to prevent HIV infection

Links

Series:

• Antivirals

Categories:

• Biochemistry
• Clinical Practice
• Microbiology
• Pharmaceutical Sciences

Therapeutic Areas:

• Infectious Diseases

Talk Citation

Publication History

• Published on August 30, 2011

Financial Disclosures

• Prof. José Esté has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.